Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 22

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 22
---
 Stock, we will not be able to pay full dividends on Series B Preferred Stock.

When dividends are not paid in full on the shares
of Series B Preferred Stock and any other parity equity shares for a dividend period, all dividends declared with respect to shares
of Series B Preferred Stock and all parity equity shares for such dividend period shall be declared pro rata so that the respective
amounts of such dividends bear the same ratio to each other as all accrued but unpaid dividends per share on the shares of Series B
Preferred Stock for such dividend period and all parity equity shares for such dividend period bear to each other. Therefore, if we are
not paying full dividends on any outstanding parity equity shares, including the Series A Preferred Stock, we will not be able to
pay full dividends on Series B Preferred Stock.

There may be future sales of Series B Preferred Stock, which may adversely affect the market price of the Series B Preferred Stock.

We are not restricted from issuing additional
shares of Series B Preferred Stock or securities similar to the Series B Preferred Stock including any securities that are convertible
into or exchangeable for, or that represent the right to receive, the Series B Preferred Stock. Holders of the Series B Preferred
Stock have no preemptive rights that entitle holders to purchase their pro rata share of any offering of shares of any class or
series. The market price of the Series B Preferred Stock could decline as a result of sales of additional shares of Series B
Preferred Stock made after this offering or the perception that such sales could occur. Because our decision to issue securities in any
future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing
or nature of our future offerings.

Our management team has broad discretion in the use of the proceeds of this offering and we may invest or spend such proceeds in ways with which you may not agree or in ways that may not yield a significant return.

Our management will have broad discretion over
the use of the proceeds from this offering. The net proceeds from this offering will be used for general corporate purposes, which may
include funding new acquisitions and repaying indebtedness, including amounts outstanding under our Credit Facility. Our management will
have considerable discretion in the application of such net proceeds, and you will not have the opportunity, as part of your investment
decision, to assess whether such proceeds are being used appropriately. As a result, the net proceeds from this offering may be used for
purposes that do not increase our operating